Biosimilars: development and investigation using achievements in modern biotechnology
Biosimilars are biological drug products that have an equivalent clinical profile with innovator biotherapeutics but are developed under a reduced program. To this end, specific comparability approaches are followed based on reverse engineering that involves a thorough analysis of the innovator biot...
Saved in:
Main Authors: | R. R. Niyazov, M. A. Dranitsyna, A. N. Vasiliev, E. V. Gavrishina |
---|---|
Format: | article |
Language: | EN RU |
Published: |
Endocrinology Research Centre
2021
|
Subjects: | |
Online Access: | https://doaj.org/article/3890df950eda4cfaab3a564c6fd838b2 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Biosimilars: presumption of guilt
by: Marina Vladimirovna Shestakova, et al.
Published: (2011) -
Modern approach to the evaluation of the pharmacokinetics and pharmacodynamics of biosimilar recombinant human insulin and insulin analogues in I phase clinical study
by: Irina A. Proskurina, et al.
Published: (2016) -
Russian association of endocrinologist draft recommendation on insulin biosimilars using
by: I. I. Dedov, et al.
Published: (2021) -
Evaluation of biosimilarity of RinGlar® (GEROPHARM LLC, Russia) and Lantus® (Sanofi-Aventis Deutschland GmbH, Germany) using the euglycemic hyperinsulinemic clamp technique in patients with type 1 diabetes: double-blind randomized clinical trial
by: Alexander Y. Mayorov, et al.
Published: (2020) -
Assessment the equivalence of the bioanalogue insulin lizpro biphasic 25 (Geropharm-bio, Russia) and Humalog® Mix 25 (Lilly France, France) using the euglycemic hyperinsulinum clamp method on healthy volonters
by: Alexander Y. Mayorov, et al.
Published: (2018)